Jul 17, 2026Effective9999999995-26-002352
All companies
Trade Decoy Therapeutics Inc424B4Nov 12, 2025
DE
Decoy Therapeutics Inc
DCOYPublic
PublicUnited States(Nasdaq)Best valuation $2.4M1 market
Public listing
Listed· Nasdaq· Listing market: United StatesListing date
Jun 26, 2026
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-edgar, sec-harvest, nasdaq
IPO Calendar · NasdaqIPO
DCOYPrice
$4.06
24h
-3.10%
Valuation
$2.4M
24h volume
$523.41K
Type
IPO
Trade Decoy Therapeutics IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 1h ago
Decoy Therapeutics Inc IPO public float & lock-up
Public float and locked shares extracted from Decoy Therapeutics Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Total shares (FD)
5.72M
Public float
2.51M
Locked
3.2M
IPO raise
—
Next unlock
—
Needs review: Could not extract a detailed lock-up release schedule.
Financials
ProfitableFrom SEC filings, latest FY ending Dec 31, 2022 · CIK 0001615219.
Revenue · -100.00% YoY
$0
Net income
$12.52M
Gross margin
—
Cash
$10.71M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $1.84M |
| Operating income | -$12.61M | -$5.73M | -$12.89M | -$31.84M | -$12.81M |
| Net income | $12.52M | $5.58M | $12.54M | -$31.61M | -$12.77M |
| R&D expense | $368.17K | $770.03K | $7.17M | $15.84M | $8.55M |
| Cash & equivalents | $10.71M | $2.43M | $5.9M | $12.11M | $29.21M |
| Total assets | $11.06M | $3.02M | $6.59M | $14.65M | $40.83M |
| Total liabilities | $5.17M | $1.51M | $1.3M | $4.27M | $2.11M |
| Shareholders' equity | $5.89M | $1.51M | $5.29M | $10.38M | $38.72M |
About Decoy Therapeutics Inc
Decoy Therapeutics is a preclinical biotechnology company developing peptide-conjugate therapeutics using machine learning, AI tools, and high-speed synthesis.
What the company does
- Uses its IMP3ACT platform to engineer, optimize, and manufacture peptide conjugates.
- Initially targets infectious diseases and oncology indications with serious unmet medical needs.
- Builds a drug pipeline that remains preclinical and has not yet produced approved commercial products.
Business profile
Decoy Therapeutics operates in early-stage biopharma, where platform validation, preclinical data, financing, clinical trial design, and regulatory execution determine value.
SEC IPO filings
EffectiveEDGAR filings resolved from DCOY / CIK 0001615219.
424B3424B3
Jul 17, 2026Final prospectus0001193125-26-307982
S-1S-1
Jul 10, 2026Filed0001193125-26-300954
Jun 24, 2026Effective9999999995-26-002113
S-1S-1
Jun 15, 2026Filed0001193125-26-269891
RWRW
Jun 5, 2026Withdrawn0001193125-26-259729
424B4424B4
Nov 12, 2025Final prospectus0001628280-25-051365
FWPFWP
Nov 10, 2025Free writing prospectus0001615219-25-000157
S-1/AS-1/A
Oct 21, 2025Amended0001628280-25-045619
FWPFWP
Sep 26, 2025Free writing prospectus0001615219-25-000137
S-1/AS-1/A
Sep 23, 2025Amended0001628280-25-042500
CORRESPfilename1.htm
Aug 11, 2025SEC correspondence0001615219-25-000093
Decoy Therapeutics Inc IPO — frequently asked questions
- When did Decoy Therapeutics Inc go public?
- Decoy Therapeutics Inc completed its IPO on Jun 26, 2026 on Nasdaq under the ticker DCOY and now trades publicly.
- Can I buy Decoy Therapeutics Inc stock?
- Yes — Decoy Therapeutics Inc is publicly traded on Nasdaq as DCOY. You can follow its live price, valuation and post-IPO performance above.
- What is Decoy Therapeutics Inc's valuation?
- Decoy Therapeutics Inc's most recent valuation tracked here is $2.4M, derived from live market prices.